Tools

Gastroenterology

Back to Results

Jatin Roper, MD accepting new patients


Overview

Programs + Specialties
Research Interests Colorectal cancer, intestinal stem cells, mouse models of colorectal cancer, intestinal biology, regulation of intestinal cancer by Akt/PKB and Tpl2 kinase, intestinal epithelial cells, cancer stem cells, intestinal organoids, CRISPR/Cas9 gene editing
Training + Education Boston University School of Medicine; NYU School of Medicine; Tufts Medical Center
Board Certifications Internal Medicine, Gastroenterology and Hepatology
NPI # 1124273461
Gender Male
Language(s) Hindi, Spanish

Locations + Directions

Tufts Medical Center
Proger Building, 3rd Floor
800 Washington St.
Box 233
Boston, MA 02111
Fax #: 617-636-4505
Phone #: 617-636-5883

Honors + Awards

2015, AGA Future Leaders Program Member, American Gastroenterological Association
2012, AGA Academic Skills Workshop Grant Recipient, American Gastroenterological Association
2011, Investing in the Future: Clinical Research in IBD Award, American Gastroenterological Association (AGA) Institute
2011, Fellowship2Leadership Gastroenterology/Hepatology Fellows’ Travel Grant 2011 Salix Pharmaceuticals
2011, ACG Travel Award for Outstanding Clinical Research Presentation 2011 North American Conference for GI Fellows, American College of Gastroenterology
2011, Oral presentation, Gastrointestinal Oncology Section, Distinguished Abstracts Plenary Digestive Disease Week
2010, 2nd place for Outstanding Poster, Tufts Medical Center Cancer Center Retreat
2006, Michael Saperstein Medical Scholar, New York University Department of Medicine
2004, Alumni Association Award, Boston University School of Medicine
2001, David E. Rogers Fellowship, New York Academy of Medicine
2001, Magna Cum laude, Boston University

Publications + National Presentations

1. Roper, J., Francois, F., Shue, P.L., Mourad, M., Pei, Z., Olivares, A.Z., Perez-Perez, G.I., Tseng, C.H., Blaser, M.J. Leptin and ghrelin in relation to Helicobacter pylori status in male veterans. Journal of Clinical Endocrinology and Metabolism 2008; 93(6):2350-7. PMID: 18397989, PMCID: 2435636

2. Roper, J., Richardson, M.P., Wang, W.V., Georgeon Richard, L., Chen, W., Coffee, E.M., Sinnamon, M.J., Lee, L., Chen, P., Bronson, R.T., Martin, E.S., Hung, K.E. The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer. PLoS ONE 2011;6(9):e25132. PMID: 21966435, PMCID: 3180374

3. Roper, J., Hung, K.E. Priceless "GEMMs": Genetically Engineered Mouse Models for Colorectal Cancer Drug Development. Trends in Pharmacological Sciences 2012 Aug;33(8):449-55. PMID: 22739258.

4. Martin, E.S., Belmont, P.J., Sinnamon, M.J., Georgeon Richard, L., Yuan, J., Coffee, E., Roper, J., Lee, L., Heidari, P., Lunt, S.Y., Goel, G., Ji, C., Xie, J., Xie, T., Lamb, J., Weinrich, S., Vanarsdale, T.L., Bronson, R.T., Xavier, R.J., Vander Heiden, M., Kan, J., Mahmood, U., Hung, K.E. Development of a Colon Cancer GEMM-Derived Orthotopic Transplant Model for Drug Discovery and Validation. Clin Cancer Res. 2013 Jun 1;19(11):2929-40. PMID: 23403635

5. Coffee, E.M., Faber, A.C., Roper, J., Sinnamon, M.J., Goel, G., Keung, L., Wang, W.V., Vecchione, L., de Vriendt, V., Weinstein, B.J., Bronson, R.T., Tejpar, S., Xavier, R.J., Engelman, J.A., Martin, E.S., Hung, K.E. Concomitant BRAF and PI3K/mTOR Blockade Is Required for Effective Treatment of BRAFV600E Colorectal Cancer. Clin Cancer Res. 2013 May 15;19(10):2688-98. PMID: 23549875, NIHMS 461193

6. Faber A.C., Coffee E.M., Costa C., Dastur A., Ebi H., Hata A.N., Yeo A.T., Edelman E.J., Song Y., Tam A.T., Boisvert J.L., Milano R.J., Roper J., Kodack D.P., Jain R.K., Corcoran R.B., Rivera M.N., Ramaswamy S., Hung K.E., Benes C.H., Engelman J.A. mTOR Inhibition Specifically Sensitizes Colorectal Cancers with KRAS or BRAF Mutations to BCL-2/BCL-XL Inhibition by Suppressing MCL-1. Cancer Discov. 2014 Jan;4(1):42-52. PMID: 24163374

7. Roper J., Sinnamon M.J., Coffee E.M., Belmont P., Keung L., Georgeon-Richard L., Wang W.V., Faber A.C., Yun J., Yilmaz O.H., Bronson R.T., Martin E.S., Tsichlis P.N., Hung K.E. Combination PI3K/MEK inhibition promotes tumor apoptosis and regression in PIK3CA wild-type, KRAS mutant colorectal cancer. Cancer Lett. 2014 Jun 1;347(2):204-11. PMID: 24576621, PMCID: 4118771

8. Roper J., Martin E.S., Hung K.E. Genetically Engineered Mouse Models of Colorectal Carcinoma to Enable Translational Biology and Drug Development. Curr Protoc Pharmacol. 2014 Jun 16;65:14.29.1-14.29.10. PMID: 24934606

9. Belmont P.J., Budinska E., Jiang P., Sinnamon M.J., Coffee E., Roper J., Xie T., Rejto P.A., Derkits S., Sansom O.J., Delorenzi M., Tejpar S., Hung K.E., Martin E.S.. Cross-species analysis of genetically engineered mouse models of MAPK driven colorectal cancer identifies hallmarks of human disease. Dis Model Mech. 2014 Jun;7(6):613-23. PMID: 24742783, PMCID: 4036469

10. Paul S., Sepehr G.J., Weinstein B., Roper J. Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. Dig Dis Sci. 2014 Nov;59(11):2831-5. PMID: 25108519

11. Belmont P.J., Jiang P., McKee T.D., Xie T., Isaacson J., Baryla N.E., Roper J., Sinnamon M.J., Lee N.V., Kan J.L., Guicherit O., Wouters B.G., O'Brien C.A., Shields D., Olson P., VanArsdale T., Weinrich S.L., Rejto P., Christensen J.G., Fantin V.R., Hung K.E., Martin E.S. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR. Sci Signal. 2014 Nov 11;7(351):ra107. PMID: 25389372, PMCID:

Biography

Jatin Roper, MD, is the Director of the Center for Hereditary Gastrointestinal Cancer at Tufts Medical Center. He attended college and medical school at Boston University through the Seven-Year Liberal Arts/Medical Education Program, followed by residency training in Internal Medicine at NYU Medical Center and fellowship training in Gastroenterology and Hepatology at Tufts Medical Center. As a postdoctoral fellow in the laboratories of Drs. Kenneth Hung and Philip Tsichlis, Dr. Roper developed a research interest in mechanisms of colorectal carcinogenesis. His work, published in two first-author papers, elucidated the role of PI3K/Akt inhibition in PIK3CA wild-type colorectal cancer using novel mouse models. As a junior faculty member of the Molecular Oncology Research Institute at Tufts Medical Center, Dr. Roper studies the molecular regulation of intestinal stem cell regeneration and colorectal tumorigenesis using mouse and human-derived intestinal organoids or “mini-intestines”, genetically engineered mouse models of cancer, and an orthotopic transplant model of colorectal cancer. He is funded by the Department of Defense, the V Foundation for Cancer Research, the Earl P. Charlton Fund Research Award, and the Rozan Research Fund Pilot Award. He has co-authored 14 peer-reviewed publications and one book chapter.

News, Media + Videos

Jatin Roper, MD is a gastroenterologist at Tufts Medical Center in downtown Boston, MA.

Dr. Jatin Roper provides updates on Colorectal Cancer Syndromes on QuantiaMD.

Read More
A drawing of gastro for Tufts Medical Center in downtown Boston, MA.

Jatin Roper, MD is co-lead author of potentially groundbreaking research into the effect of a high-fat diet and colorectal cancer.

Read More
Jatin Roper, MD is a gastroenterologist at Tufts Medical Center in downtown Boston, MA.

Tufts Medical Center launches multidisciplinary Center for Hereditary Gastrointestinal Cancers.

Read More